Anjarium Biosciences AG (Anjarium), a biotech company focused on creating and delivering a new class of non-viral gene therapies, announces the expansion of its Board of Directors with the appointments of Gaurav Shah, MD and Douglas Fambrough, PhD as independent Non-executive Directors. Gaurav Shah is also named as Chairperson of the Board. Stephen Yoo, Anjarium’s Chief Executive Officer, said: “I…